ALS THERAPY DEVELOPMENT FOUNDATION INC

EIN: 043462719 501(c)(3) Medical Research

WATERTOWN, MA

Total Revenue
$16,066,902
Total Expenses
$13,127,937
Total Assets
$22,324,694
Net Assets
$19,257,404
🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Sign In — Free (10 views/day)

Financial Trends

Organization Details

Formation Year
1999
Legal Domicile
MA
Principal Officer
DR FERNANDO VIEIRA
Phone
6174417200
Tax Period
2025-01-01 to 2025-12-31

ALS THERAPY DEVELOPMENT FOUNDATION INC, founded in 1999, is a mid-sized nonprofit in the Medical Research sector that reported $16.1M in total revenue in fiscal year 2025. Revenue grew 20% year-over-year, indicating healthy expansion. The organization ran a surplus of $2.9M, a strong 18% operating margin.

Mission

OUR MISSION IS TO IDENTIFY VIABLE TARGETS FOR THERAPY DEVELOPMENT AND EXPEDITIOUSLY MANAGE THE CREATION OF THOSE TREATMENTS THAT WILL ARREST THE SUFFERING OF TODAY'S ALS PATIENTS.

Program Service Accomplishments

Program 1
Expenses: $11,887,087 Revenue: $623,964

ALS TDI COMBINES THE PASSION AND DEDICATION OF A NONPROFIT ORGANIZATION WITH THE ENTREPRENEURIAL AND SCIENTIFIC SPIRIT OF A BIOTECHNOLOGY COMPANY. OUR LABORATORY IS THE LEADING DRUG DISCOVERY PROGRAM...

Read more

ALS TDI COMBINES THE PASSION AND DEDICATION OF A NONPROFIT ORGANIZATION WITH THE ENTREPRENEURIAL AND SCIENTIFIC SPIRIT OF A BIOTECHNOLOGY COMPANY. OUR LABORATORY IS THE LEADING DRUG DISCOVERY PROGRAM FOR ALS, AND IT BRIDGES A CRITICAL RESEARCH GAP. OUR IN-HOUSE EXPERTISE TRANSLATES RESEARCH INTO POTENTIAL DRUG CANDIDATES BY SCREENING DRUGS IN THE SOD1 MOUSE MODEL OF ALS. OUR SCIENTIFIC COLLABORATIONS ARE DESIGNED TO BRING THE MOST PROMISING LEADS CLOSER TO PATIENT USE. WE SHARE EMERGING KNOWLEDGE ON THE DISEASE WITH PATIENTS, PHYSICIANS, AND RESEARCHERS AS QUICKLY AND COMPREHENSIVELY AS POSSIBLE. EVERY DECISION IS MADE IN THE INTEREST OF FINDING EFFECTIVE TREATMENTS FOR PEOPLE LIVING WITH ALS. OUR UNIQUE APPROACH ACCELERATES DRUG DEVELOPMENT FOR ALS.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Sign In — Free (10 views/day)

Financial Overview (2025)

Revenue Breakdown

Contributions & Grants $14,817,715
Program Service Revenue $623,964
Investment Income $339,712
Other Revenue $285,511
TOTAL REVENUE $16,066,902

Expense Breakdown

Grants Paid $0
Salaries & Benefits $6,093,591
Fundraising Expenses $650,129
Program Expenses $11,887,087
Other Expenses $7,002,623
TOTAL EXPENSES $13,127,937

Year-over-Year Comparison

2025 2024 Change
Revenue $16,066,902 $13,406,171 +0.2%
Expenses $13,127,937 $12,879,065 +0.0%
Net Income $2,938,965 $527,106 +4.6%
Key Indicators
✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required
🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Sign In

Governance

Voting Members
18
Independent Members
17
Employees
65
Volunteers
500

Governance Policies

✓ Conflict of Interest Policy
✓ Whistleblower Policy
✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School
✗ Operated a Hospital
✗ Provided First Class Travel
⚠ Reported Conflict of Interest
✗ Reported Asset Diversion
✗ Excess Benefit Transaction
✗ Made Political Expenditures
✗ Engaged in Lobbying
✗ Operated Donor Advised Fund
✗ Maintained Art Collections
✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers
4
$472,042
Total Directors
18
$472,042
Key Employees
0
$0
Highest Compensated
5
reported
Name Title Hours/Week Role Reportable Comp Other Comp Total
FERNANDO VIEIRA CEO AND CSO 40.00
Officer Director
$436,433 $35,609 $472,042
LYNNE NIETO BOARD CHAIR 2.50
Officer Director
$0 $0 $0
STEVEN PERRIN PHD VICE CHAIR 2.50
Officer Director
$0 $0 $0
THEODORE REICH JD CPA TREASURER AND BOARD MEMBER 2.50
Officer Director
$0 $0 $0
DR STANLEY H APPEL MD BOARD MEMBER 2.50
Director
$0 $0 $0
ALEXANDER CAPPELLO BOARD MEMBER 2.50
Director
$0 $0 $0
DR SPIROS JAMAS SCD BOARD MEMBER 2.50
Director
$0 $0 $0
JAMES ALLEN HEYWOOD BOARD MEMBER 2.50
Director
$0 $0 $0
JOHN B HEYWOOD PHD SCD BOARD MEMBER 2.50
Director
$0 $0 $0
ROB RODIN BOARD MEMBER 2.50
Director
$0 $0 $0
PAUL SALLABERRY BOARD MEMBER 2.50
Director
$0 $0 $0
ROBERT SEPUCHA BOARD MEMBER 2.50
Director
$0 $0 $0
JENNY DWYER BOARD MEMBER 2.50
Director
$0 $0 $0
MIKE SMITH BOARD MEMBER 2.50
Director
$0 $0 $0
JULIE SWAN BOARD MEMBER 2.50
Director
$0 $0 $0
KENT JACKSON BRANSFORD MD BOARD MEMBER 2.50
Director
$0 $0 $0
TOM ENGELLENNER BOARD MEMBER 2.50
Director
$0 $0 $0
JAY AGARWAL BOARD MEMBER 2.50
Director
$0 $0 $0
ALAN GILL VP OF RESEARCH 40.00
Highest
$194,572 $12,913 $207,485
CAROL HAMILTON SENIOR VP OF DEVELOPMENT 40.00
Highest
$177,160 $9,765 $186,925
KYLE R DENTON SENIOR DIRECTOR, CELL BIOLOGY 40.00
Highest
$173,063 $9,391 $182,454
THEO HATZIPETROS SENIOR DIRECTOR OF PHARMACOLOGY 40.00
Highest
$161,717 $13,010 $174,727
DANIELLE BOYCE PRINC. INVEST., REAL WORLD EVIDENCE 40.00
Highest
$139,506 $4,817 $144,323
Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year Revenue Expenses Assets Net Income
2025 $16,066,902 $13,127,937 $22,324,694 $2,938,965
2024 $13,406,171 $12,879,065 $23,052,170 $527,106
2023 $11,558,482 $11,160,593 $20,012,651 $397,889
2022 $11,364,169 $9,829,539 $21,051,525 $1,534,630
2021 $12,370,651 $8,987,486 $19,047,011 $3,383,165
2020 $10,248,613 $9,529,307 $29,996,989 $719,306
2019 $13,129,736 $11,458,890 $17,469,547 $1,670,846
2018 $15,038,596 $12,329,559 $15,652,260 $2,709,037
Explore More Nonprofits
→Top 100 Nonprofits in Massachusetts →Largest U.S. Nonprofits →Best Rated Nonprofits →Most Efficient Nonprofits

Compare ALS THERAPY DEVELOPMENT FOUNDATION INC with other nonprofits in Massachusetts and across the country.

We Value Your Privacy
We use cookies and similar technologies to analyze site traffic and improve your experience. By clicking "Accept All", you consent to our use of cookies for analytics and measurement.